Risk  ||| S:0 E:5 ||| NN
of  ||| S:5 E:8 ||| IN
seizure  ||| S:8 E:16 ||| NN
recurrence  ||| S:16 E:27 ||| NN
after  ||| S:27 E:33 ||| IN
a  ||| S:33 E:35 ||| DT
first  ||| S:35 E:41 ||| JJ
unprovoked  ||| S:41 E:52 ||| JJ
seizure  ||| S:52 E:60 ||| NN
in  ||| S:60 E:63 ||| IN
childhood  ||| S:63 E:73 ||| NN
To  ||| S:73 E:76 ||| TO
assess  ||| S:76 E:83 ||| VB
the  ||| S:83 E:87 ||| DT
risk  ||| S:87 E:92 ||| NN
of  ||| S:92 E:95 ||| IN
recurrence  ||| S:95 E:106 ||| NN
after  ||| S:106 E:112 ||| IN
a  ||| S:112 E:114 ||| DT
first  ||| S:114 E:120 ||| JJ
unprovoked  ||| S:120 E:131 ||| JJ
seizure  ||| S:131 E:139 ||| NN
in  ||| S:139 E:142 ||| IN
childhood ||| S:142 E:151 ||| NN
.  ||| S:151 E:153 ||| .
This  ||| S:153 E:158 ||| DT
was  ||| S:158 E:162 ||| VBD
a  ||| S:162 E:164 ||| DT
prospective  ||| S:164 E:176 ||| JJ
study  ||| S:176 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
250  ||| S:185 E:189 ||| CD
children  ||| S:189 E:198 ||| NNS
aged  ||| S:198 E:203 ||| VBN
1  ||| S:203 E:205 ||| CD
month  ||| S:205 E:211 ||| NN
to  ||| S:211 E:214 ||| TO
16  ||| S:214 E:217 ||| CD
years  ||| S:217 E:223 ||| NNS
after  ||| S:223 E:229 ||| IN
a  ||| S:229 E:231 ||| DT
first  ||| S:231 E:237 ||| JJ
seizure  ||| S:237 E:245 ||| NN
who  ||| S:245 E:249 ||| WP
presented  ||| S:249 E:259 ||| VBD
between  ||| S:259 E:267 ||| IN
November  ||| S:267 E:276 ||| NNP
1 ||| S:276 E:277 ||| CD
,  ||| S:277 E:279 ||| ,
2008  ||| S:279 E:284 ||| CD
and  ||| S:284 E:288 ||| CC
October  ||| S:288 E:296 ||| NNP
31 ||| S:296 E:298 ||| CD
,  ||| S:298 E:300 ||| ,
2012 ||| S:300 E:304 ||| CD
.  ||| S:304 E:306 ||| .
None  ||| S:306 E:311 ||| NN
of  ||| S:311 E:314 ||| IN
the  ||| S:314 E:318 ||| DT
children  ||| S:318 E:327 ||| NNS
was  ||| S:327 E:331 ||| VBD
treated  ||| S:331 E:339 ||| VBN
after  ||| S:339 E:345 ||| IN
the  ||| S:345 E:349 ||| DT
first  ||| S:349 E:355 ||| JJ
seizure ||| S:355 E:362 ||| NN
.  ||| S:362 E:364 ||| .
Recurrence  ||| S:364 E:375 ||| JJ
rates  ||| S:375 E:381 ||| NNS
were  ||| S:381 E:386 ||| VBD
calculated  ||| S:386 E:397 ||| VBN
by  ||| S:397 E:400 ||| IN
Kaplan-Meier  ||| S:400 E:413 ||| JJ
survival  ||| S:413 E:422 ||| NN
analysis ||| S:422 E:430 ||| NN
,  ||| S:430 E:432 ||| ,
and  ||| S:432 E:436 ||| CC
univariate  ||| S:436 E:447 ||| JJ
analyses  ||| S:447 E:456 ||| NNS
for  ||| S:456 E:460 ||| IN
recurrence  ||| S:460 E:471 ||| JJ
risk  ||| S:471 E:476 ||| NN
were  ||| S:476 E:481 ||| VBD
performed  ||| S:481 E:491 ||| VBN
using  ||| S:491 E:497 ||| VBG
the  ||| S:497 E:501 ||| DT
Cox  ||| S:501 E:505 ||| NNP
proportional  ||| S:505 E:518 ||| VBD
hazards  ||| S:518 E:526 ||| JJ
model ||| S:526 E:531 ||| NN
.  ||| S:531 E:533 ||| .
One  ||| S:533 E:537 ||| CD
hundred  ||| S:537 E:545 ||| CD
and  ||| S:545 E:549 ||| CC
thirty-five  ||| S:549 E:561 ||| JJ
children  ||| S:561 E:570 ||| NNS
( ||| S:570 E:571 ||| -LRB-
54 ||| S:571 E:573 ||| CD
% ||| S:573 E:574 ||| NN
)  ||| S:574 E:576 ||| -RRB-
had  ||| S:576 E:580 ||| VBD
recurrence ||| S:580 E:590 ||| NN
.  ||| S:590 E:592 ||| .
Thirty-seven  ||| S:592 E:605 ||| NNP
( ||| S:605 E:606 ||| -LRB-
27 ||| S:606 E:608 ||| CD
% ||| S:608 E:609 ||| NN
)  ||| S:609 E:611 ||| -RRB-
of  ||| S:611 E:614 ||| IN
the  ||| S:614 E:618 ||| DT
recurrences  ||| S:618 E:630 ||| NN
occurred  ||| S:630 E:639 ||| VBD
in  ||| S:639 E:642 ||| IN
the  ||| S:642 E:646 ||| DT
first  ||| S:646 E:652 ||| JJ
month ||| S:652 E:657 ||| NN
,  ||| S:657 E:659 ||| ,
71  ||| S:659 E:662 ||| CD
( ||| S:662 E:663 ||| -LRB-
53 ||| S:663 E:665 ||| CD
% ||| S:665 E:666 ||| NN
)  ||| S:666 E:668 ||| -RRB-
within  ||| S:668 E:675 ||| IN
3  ||| S:675 E:677 ||| CD
months ||| S:677 E:683 ||| NNS
,  ||| S:683 E:685 ||| ,
95  ||| S:685 E:688 ||| CD
( ||| S:688 E:689 ||| -LRB-
70 ||| S:689 E:691 ||| CD
% ||| S:691 E:692 ||| NN
)  ||| S:692 E:694 ||| -RRB-
within  ||| S:694 E:701 ||| IN
6  ||| S:701 E:703 ||| CD
months ||| S:703 E:709 ||| NNS
,  ||| S:709 E:711 ||| ,
and  ||| S:711 E:715 ||| CC
118  ||| S:715 E:719 ||| CD
( ||| S:719 E:720 ||| -LRB-
87 ||| S:720 E:722 ||| CD
% ||| S:722 E:723 ||| NN
)  ||| S:723 E:725 ||| -RRB-
within  ||| S:725 E:732 ||| IN
1  ||| S:732 E:734 ||| CD
year ||| S:734 E:738 ||| NN
.  ||| S:738 E:740 ||| .
The  ||| S:740 E:744 ||| DT
risk  ||| S:744 E:749 ||| NN
of  ||| S:749 E:752 ||| IN
seizure  ||| S:752 E:760 ||| NN
recurrence  ||| S:760 E:771 ||| NN
was  ||| S:771 E:775 ||| VBD
38 ||| S:775 E:777 ||| CD
% ||| S:777 E:778 ||| NN
,  ||| S:778 E:780 ||| ,
47 ||| S:780 E:782 ||| CD
% ||| S:782 E:783 ||| NN
,  ||| S:783 E:785 ||| ,
54 ||| S:785 E:787 ||| CD
% ||| S:787 E:788 ||| NN
,  ||| S:788 E:790 ||| ,
and  ||| S:790 E:794 ||| CC
58 ||| S:794 E:796 ||| CD
%  ||| S:796 E:798 ||| NN
at  ||| S:798 E:801 ||| IN
0.5 ||| S:801 E:804 ||| CD
,  ||| S:804 E:806 ||| ,
1 ||| S:806 E:807 ||| CD
,  ||| S:807 E:809 ||| ,
2 ||| S:809 E:810 ||| CD
,  ||| S:810 E:812 ||| ,
and  ||| S:812 E:816 ||| CC
5  ||| S:816 E:818 ||| CD
years ||| S:818 E:823 ||| NNS
,  ||| S:823 E:825 ||| ,
respectively ||| S:825 E:837 ||| RB
.  ||| S:837 E:839 ||| .
The  ||| S:839 E:843 ||| DT
risk  ||| S:843 E:848 ||| NN
factors  ||| S:848 E:856 ||| NNS
for  ||| S:856 E:860 ||| IN
seizure  ||| S:860 E:868 ||| NN
recurrence  ||| S:868 E:879 ||| NN
were  ||| S:879 E:884 ||| VBD
remote  ||| S:884 E:891 ||| JJ
symptomatic  ||| S:891 E:903 ||| JJ
etiology ||| S:903 E:911 ||| NN
,  ||| S:911 E:913 ||| ,
abnormal  ||| S:913 E:922 ||| JJ
electroencephalography ||| S:922 E:944 ||| NN
,  ||| S:944 E:946 ||| ,
age  ||| S:946 E:950 ||| NN
â‰¥  ||| S:950 E:952 ||| CD
8  ||| S:952 E:954 ||| CD
years ||| S:954 E:959 ||| NNS
,  ||| S:959 E:961 ||| ,
and  ||| S:961 E:965 ||| CC
a  ||| S:965 E:967 ||| DT
history  ||| S:967 E:975 ||| NN
of  ||| S:975 E:978 ||| IN
prior  ||| S:978 E:984 ||| JJ
febrile  ||| S:984 E:992 ||| JJ
seizure  ||| S:992 E:1000 ||| NN
( ||| S:1000 E:1001 ||| -LRB-
partial  ||| S:1001 E:1009 ||| JJ
seizure ||| S:1009 E:1016 ||| NN
) ||| S:1016 E:1017 ||| -RRB-
.  ||| S:1017 E:1019 ||| .
Children  ||| S:1019 E:1028 ||| NNS
should  ||| S:1028 E:1035 ||| MD
not  ||| S:1035 E:1039 ||| RB
be  ||| S:1039 E:1042 ||| VB
routinely  ||| S:1042 E:1052 ||| RB
treated  ||| S:1052 E:1060 ||| VBN
after  ||| S:1060 E:1066 ||| IN
a  ||| S:1066 E:1068 ||| DT
first  ||| S:1068 E:1074 ||| JJ
seizure ||| S:1074 E:1081 ||| NN
,  ||| S:1081 E:1083 ||| ,
and  ||| S:1083 E:1087 ||| CC
it  ||| S:1087 E:1090 ||| PRP
is  ||| S:1090 E:1093 ||| VBZ
important  ||| S:1093 E:1103 ||| JJ
that  ||| S:1103 E:1108 ||| IN
we  ||| S:1108 E:1111 ||| PRP
consider  ||| S:1111 E:1120 ||| VBP
the  ||| S:1120 E:1124 ||| DT
recurrence  ||| S:1124 E:1135 ||| JJ
rate  ||| S:1135 E:1140 ||| NN
and  ||| S:1140 E:1144 ||| CC
risk ||| S:1144 E:1148 ||| NN
.  ||| S:1148 E:1150 ||| .
